DELTA-Q-TECHNOLOGIES
Delta-Q Technologies (Delta-Q), a leader in battery charging solutions for electric vehicles and industrial equipment, has announced that its innovative mid-power charger, the XV3300, is now in full-scale production. With its unique 3-in-1 design, this highly efficient charging system integrates a 3.3 kW battery charger, a 500 W DC-DC converter to power the vehicles’ auxiliary loads, and an EV charging station interface. These key features, encased in a ruggedized IP67 design, provide OEMs with an attractive package for simplifying electrification of their off-road applications.
“No other 3.3 kW charger on the market also includes a DC/DC converter for auxiliary DC loads and an EVSE charging interface in such a compact size,” said Mourad Chergui, Senior Product Manager with Delta-Q. “As we start full-scale production, we can begin to fulfill the substantial demand we received since we first announced the initial development.”
The 3.3 kW charging solution is available in 58.8, 65, and 120-volt DC models and is scalable, allowing OEMs to stack up to three chargers for power levels up to 10 kW. The XV3300 uses complex algorithms to deliver a precise charge to batteries of various chemistries and voltages, maximizing battery life and optimizing charge time.
Key features and benefits of the XV3300 charger include:
- High Reliability: The XV3300 battery charger is compact, rugged, and IP67-rated. It is tested for automotive-grade shock and vibration. Its fully sealed aluminum die-cast enclosure protects the charger from dust, liquids, and the effects of immersion in up to one meter of water.
- Enhanced Protection: The XV3300 is a low-voltage charger that optimally charges all battery chemistries and nominal voltages between 48 V to 120 V. It is also protected against short circuits, over-voltage, and over-temperature to ensure safe operation.
- Flexible Power Options: The XV3300 is scalable and can be paralleled to provide between 3.3 kW to 10 kW of power for faster-charging options. The charger is also available as an on-board and off-board charger, providing OEMs with additional flexibility.
- Integrated DC-DC converter: It provides auxiliary power to operate vehicle accessories such as air-conditioners, controllers, lights, turn signals, navigation, and communication devices. It also eliminates the need for an external DC-DC converter, saving OEMs and equipment operators space and cost.
- EV Charging Station Interface: The XV3300 complies with SAE J1772 (levels 1 and 2) and IEC 61851 (modes 2 and 3) to charge from standard EVSE AC charging stations across North America and Europe. This feature provides end-users more charging options and greater vehicle flexibility.
To register for updates on the XV3300 battery charger or for specific details, including product specifications, visit https://connect.delta-q.com/xv3300.
About Delta-Q Technologies
Delta-Q Technologies is charging the future and driving the world’s transition to electric energy. We collaboratively design, test, and manufacture robust battery chargers that improve the performance of our customers’ electric drive vehicles and industrial machines. As the supplier of choice for Tier 1 OEMs, our customer support and engineering expertise guide our customers through the electrification process for a sustainable world.
Delta-Q is part of the ZAPI GROUP of companies and headquartered in Vancouver, Canada. The team and distribution span five continents to service industries such as electric golf cars, lift trucks, aerial work platforms, e-mobility, floor care machines, utility/recreational vehicles, and new markets, like construction and outdoor power equipment. Please visit www.delta-q.com or follow company updates on LinkedIn for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom